Headache and Methemoglobinemia.
International Classification of Headache Disorders
cyanosis
hypoxia
methemoglobin percentage
methemoglobinemia
secondary headaches
Journal
Headache
ISSN: 1526-4610
Titre abrégé: Headache
Pays: United States
ID NLM: 2985091R
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
accepted:
23
10
2019
pubmed:
15
11
2019
medline:
6
5
2021
entrez:
15
11
2019
Statut:
ppublish
Résumé
This basic review is intended to summarize the current knowledge of methemoglobinemia as an important cause of secondary headache with the hope of generating a growing interest in studying this phenomenon. We describe the pathological underpinnings of headaches generated by hypoxia. Possible mechanisms include cerebral vasodilation-associated stretching of the vessel nociceptors, sensitization of perivascular nociceptors mediated by nitric oxide, cerebral calcitonin gene-related peptide, activation of the cyclic adenosine monophosphate pathway, cortical spreading depression, disruption of the blood-brain barrier, and neurogenic inflammation. We review the clinical features, pathophysiology, and management of methemoglobinemia. We conducted a literature review of reports of symptomatic methemoglobinemia with headache. In addition, we describe a case report of a patient who presented with an acute onset of severe holocranial headache associated with rapidly progressive perioral paresthesia, cyanosis in lips and hands, nausea, and mild dyspnea on exertion. These features can be misinterpreted as an acute attack of migraine with pain-related hyperventilation syndrome and anxiety leading to clinically detrimental delay in the management of the progressive hypoxia. Her symptoms resolved following treatment with methylene blue. The complex relationship of migraine and hypoxia-related headaches is also reviewed. We propose that methemoglobinemia-associated headaches are possibly generated by stretching of the nociceptor nerve endings during cerebral vasodilation and hypoxia-mediated oxidative stress. The case highlights the need to broaden the formulated differential diagnosis of an acute onset severe holocranial headache and pay careful attention to other signs and symptoms that may provide hints on potential mechanism(s) for secondary headaches. We provide justification for the need to incorporate "Headache attributed to Methemoglobinemia" as a subtype under the section "Headache attributed to hypoxia and/or hypercapnia" of the International Classification of Headache Disorders to support clinical decision making.
Sections du résumé
AIM
This basic review is intended to summarize the current knowledge of methemoglobinemia as an important cause of secondary headache with the hope of generating a growing interest in studying this phenomenon.
BACKGROUND
We describe the pathological underpinnings of headaches generated by hypoxia. Possible mechanisms include cerebral vasodilation-associated stretching of the vessel nociceptors, sensitization of perivascular nociceptors mediated by nitric oxide, cerebral calcitonin gene-related peptide, activation of the cyclic adenosine monophosphate pathway, cortical spreading depression, disruption of the blood-brain barrier, and neurogenic inflammation. We review the clinical features, pathophysiology, and management of methemoglobinemia. We conducted a literature review of reports of symptomatic methemoglobinemia with headache. In addition, we describe a case report of a patient who presented with an acute onset of severe holocranial headache associated with rapidly progressive perioral paresthesia, cyanosis in lips and hands, nausea, and mild dyspnea on exertion. These features can be misinterpreted as an acute attack of migraine with pain-related hyperventilation syndrome and anxiety leading to clinically detrimental delay in the management of the progressive hypoxia. Her symptoms resolved following treatment with methylene blue. The complex relationship of migraine and hypoxia-related headaches is also reviewed. We propose that methemoglobinemia-associated headaches are possibly generated by stretching of the nociceptor nerve endings during cerebral vasodilation and hypoxia-mediated oxidative stress.
CONCLUSIONS
The case highlights the need to broaden the formulated differential diagnosis of an acute onset severe holocranial headache and pay careful attention to other signs and symptoms that may provide hints on potential mechanism(s) for secondary headaches. We provide justification for the need to incorporate "Headache attributed to Methemoglobinemia" as a subtype under the section "Headache attributed to hypoxia and/or hypercapnia" of the International Classification of Headache Disorders to support clinical decision making.
Substances chimiques
Enzyme Inhibitors
0
Methylene Blue
T42P99266K
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
291-297Informations de copyright
© 2019 American Headache Society.
Références
Jaffé ER. Methemoglobin pathophysiology. Prog Clin Biol Res. 1981;51:133-151.
Mansouri A, Lurie AA. Methemoglobinemia. Am J Hematol. 1993;42:7-12.
Barclay JA, Ziemba SE, Ibrahim RB. Dapsone-induced methemoglobinemia: A primer for clinicians. Ann Pharmacother. 2011;45:1103-1115.
Wright RO, Lewander WJ, Woolf AD. Methemoglobinemia: Etiology, pharmacology, and clinical management. Ann Emerg Med. 1999;34:646-656.
Percy MJ, Lappin TR. Recessive congenital methaemoglobinaemia: Cytochrome b(5) reductase deficiency. Br J Haematol. 2008;141:298-308.
Hegesh E, Hegesh J, Kaftory A. Congenital methemoglobinemia with a deficiency of cytochrome b5. N Engl J Med. 1986;314:757-761.
Marengo-Rowe AJ. Structure-function relations of human hemoglobins. Bayl Univ Med Cent Proc. 2006;19:239-245.
Ash-Bernal R, Wise R, Wright SM. Acquired methemoglobinemia: A retrospective series of 138 cases at 2 teaching hospitals. Medicine. 2004;83:265-273.
Hegedus F, Herb K. Benzocaine-induced methemoglobinemia. Anesth Prog. 2005;52:136-139.
Walley T, Flanagan M. Nitrite-induced methaemoglobinaemia. Postgrad Med J. 1987;63:643-644.
Fawns HT, Aldridge AG. Methaemoglobinaemia due to nitrates and nitrites in drinking-water. Br Med J. 1954;2:575-576.
Fairbanks VF. Blue gods, blue oil, and blue people. Mayo Clin Proc. 1994;69:889-892.
Skold A, Cosco DL, Klein R. Methemoglobinemia: Pathogenesis, diagnosis, and management. South Med J. 2011;104:757-761.
Chowdhary S, Bukoye B, Bhansali AM, et al. Risk of topical anesthetic-induced methemoglobinemia: A 10-year retrospective case-control study. JAMA Intern Med. 2013;173:771-776.
Kane GC, Hoehn SM, Behrenbeck TR, Mulvagh SL. Benzocaine-induced methemoglobinemia based on the Mayo Clinic experience from 28 478 transesophageal echocardiograms-incidence, outcomes, and predisposing factors. Arch Intern Med. 2007;167:1977-1982.
Price DP. Methemoglobin inducers. In: Hoffman RS, Howland M, Lewin NA, Nelson LS, Goldfrank LR, eds. Goldfrank's Toxicologic Emergencies, 10th ed. New York: McGraw-Hill; 2015:977-985.
Clifton J, Leikin JB. Methylene blue. Am J Ther. 2003;10:289-291.
Bradberry SM. Occupational methaemoglobinaemia. Mechanisms of production, features, diagnosis and management including the use of methylene blue. Toxicol Rev. 2003;22:13-27.
El-Husseini A, Azarov N. Is the threshold for treatment of methemoglobinemia the same for all? A case report and literature review. Am J Emerg Med. 2010;28:e5-e10.
Cortazzo JA, Lichtman AD. Methemoglobinemia: A review and recommendations for management. J Cardiothorac Vasc Anesth. 2014;28:1043-1047.
Curry S. Methemoglobinemia. Ann Emerg Med. 1982;11:214-221.
U. S. Food and Drug Administration. FDA Drug Safety Communication: Updated Information About the Drug Interaction Between Methylene Blue (Methylthioninium Chloride) and Serotonergic Psychiatric Medications. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-updated-information-about-drug-interaction-between-methylene-blue. Accessed September 9, 2019.
Kidd SA, Lancaster PA, Anderson JC, et al. Fetal death after exposure to methylene blue dye during mid-trimester amniocentesis in twin pregnancy. Prenat Diagn. 1996;16:39-47.
Solomon S, Lipton RB, Harris PY. Arterial stenosis in migraine: Spasm or arteriopathy? Headache. 1990;30:52-61.
Dodick DDW, David W. A phase-by-phase review of migraine pathophysiology. Headache. 2018;58:4-16.
Amin FM, Hougaard A, Schytz HW, et al. Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38. Brain. 2014;137:779-794.
Thomsen LL, Iversen HK, Brinck TA, Olesen J. Arterial supersensitivity to nitric oxide (nitroglycerin) in migraine sufferers. Cephalalgia. 1993;13:395-399.
Pietrobon D, Moskowitz MA. Chaos and commotion in the wake of cortical spreading depression and spreading depolarizations. Nat Rev Neurosci. 2014;15: 379-393.
Singhal AB, Maas MB, Goldstein JN, et al. High-flow oxygen therapy for treatment of acute migraine: A randomized crossover trial. Cephalalgia. 2017;37:730-736.
Arngrim N, Schytz HW, Britze J, et al. Migraine induced by hypoxia: An MRI spectroscopy and angiography study. Brain. 2016;139:723-737.
Schoenen J. Hypoxia, a turning point in migraine pathogenesis? Brain. 2016;139:644-647.
Yang CC, Wu ML, Deng JF. Prolonged hemolysis and methemoglobinemia following organic copper fungicide ingestion. Vet Hum Toxicol. 2004;46:321-323.
Elonen E, Neuvonen PJ, Halmekoski J, Mattila MJ. Acute dapsone intoxication: A case with prolonged symptoms. Clin Toxicol. 1979;14:79-85.
Smith PA, Lodwick J, Dartt J, Amani JR, Fagan KM. Methemoglobinemia resulting from exposure in a confined space: Exothermic self-polymerization of 4,4'-methylene diphenyl diisocyanate (MDI) material. J Occup Environ Hyg. 2017;14:D13-D21.
David SR, Nora M, Rajan R. The blood blues: A review on methemoglobinemia. J Pharmacol Pharmacother. 2018;9:1.
Luks AM, Swenson ER, Bärtsch P. Acute high-altitude sickness. Eur Respir Rev. 2017;26:160096.
Alberti A, Mazzotta G, Gallinella E, Sarchielli P. Headache characteristics in obstructive sleep apnea syndrome and insomnia. Acta Neurol Scand. 2005;111:309-316.
Ozge A, Ozge C, Kaleagasi H, Yalin OO, Unal O, Ozgür ES. Headache in patients with chronic obstructive pulmonary disease: Effects of chronic hypoxaemia. J Headache Pain. 2006;7:37-43.
Broessner G, Rohregger J, Wille M, Lackner P, Ndayisaba JP, Burtscher M. Hypoxia triggers high-altitude headache with migraine features: A prospective trial. Cephalalgia. 2016;36:765-771.
Harris AD, Murphy K, Diaz CM, et al. Cerebral blood flow response to acute hypoxic hypoxia. NMR Biomed. 2013;26:1844-1852.
Britze J, Arngrim N, Schytz HW, Ashina M. Hypoxic mechanisms in primary headaches. Cephalalgia. 2017;37:372-384.
Birk S, Petersen KA, Kruuse C, et al. The effect of circulating adenosine on cerebral haemodynamics and headache generation in healthy subjects. Cephalalgia. 2005;25:369-377.
Van Mil AH, Spilt A, Van Buchem MA, et al. Nitric oxide mediates hypoxia-induced cerebral vasodilation in humans. J Appl Physiol. 2002;92:962-966.
Hasbak P, Lundby C, Olsen NV, Schifter S, Kanstrup IL. Calcitonin gene related peptide and adrenomedullin release in humans: Effects of exercise and hypoxia. Regul Pept. 2002;108:89-95.
Ben-Haim G, Armstead WM. Stimulus duration-dependent contribution of k(ca) channel activation and cAMP to hypoxic cerebrovasodilation. Brain Res. 2000;853:330-337.
Borkum JM. Migraine triggers and oxidative stress: A narrative review and synthesis. Headache. 2016;56:12-35.
Brennan KC, Charles A. An update on the blood vessel in migraine. Curr Opin Neurol. 2010;23:266-274.
Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol. 1988;23:193-196.
Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1-211.
Do TP, Remmers A, Schytz HW, et al. Red and orange flags for secondary headaches in clinical practice: SNNOOP10 list. Neurology. 2019;92:134-144.
Masavkar SS, Mauskar A, Patwardhan G, Bhat V, Manglani MV. Acquired methemoglobinemia-A sporadic Holi disaster. Indian Pediatr. 2017;54:473-475.
Sajal D. Assessment of severity of methaemoglobinemia following fibreoptic bronchoscopy with lidocaine. Indian J Chest Dis Allied Sci. 2011;53:211-214.
Murphy T, Fernandez M. Acquired methemoglobinemia from phenazopyridine use. Int J Emerg Med. 2018;11:45.
Allister L, Torres C, Schnall J, Bhatia K, Miller E. Case reports of the Harvard emergency medicine residency: Jaundice, anemia and hypoxemia. J Emerg Med. 2017;52:93-97.
Nappe TM, Pacelli AM, Katz K. An atypical case of methemoglobinemia due to self-administered benzocaine. Case Rep Emerg Med. 2015;2015:1-4.
Kilicli E, Aksel G, Akbuga ozel B, Kavalci C, Suveren artuk D. Cost of beauty; prilocaine induced Methemoglobinemia. Turk J Emerg Med. 2014;14:185-187.
Kaushik P, Zuckerman SJ, Campo NJ, Banda VR, Hayes SD, Kaushik R. Celecoxib-induced methemoglobinemia. Ann Pharmacother. 2004;38:1635-1638.
Armstrong C, Burak KW, Beck PL. Benzocaine-induced methemoglobinemia: A condition of which all endoscopists should be aware. Can J Gastroenterol Hepatol. 2004;18:625-629.